Navigation Links
Denham Capital to Invest $60 Million in VitAG, Recycler of Municipal Biosolids
Date:8/6/2008

BOSTON and BEECH ISLAND, S.C., Aug. 6 /PRNewswire/ -- Denham Capital ("Denham") announced today that it will invest up to $60 million in VitAG Corporation ("VitAG"). VitAG technology converts municipal biosolids into a value-added high-nitrogen fertilizer product capable of competing with and outperforming conventional fertilizers. The investment will fund the construction of multiple biosolids-to-fertilizer manufacturing plants.

"Denham's investment in VitAG is an opportunity for Denham to participate in the global fertilizer market in an environmentally sensitive manner," said Bill Zartler, a Managing Partner of Denham Capital. "We look forward to partnering with the innovative and experienced VitAG team on the execution of their business plan."

The VitAG process creates a sustainable and economic solution for recycling biosolids into a commercially viable fertilizer. The proprietary VitAG technology creates a granular, high-value fertilizer product that meets and exceeds the USEPA Class A and Exceptional Quality standards for biosolids-containing products. In addition, the small footprint of a VitAG manufacturing facility allows it to be located at or near existing municipal wastewater treatment plants and be sized according to the treatment plant's biosolids output, thus reducing logistical concerns and liability traditionally associated with the transportation of biosolids.

"The key to VitAG's technology is that it is environmentally-friendly," said Jeffrey C. Burnham, PhD, President and CEO of VitAG Corp. "In addition to use in traditional fertilizer markets for crops, turf, and ornamental production, VitAG fertilizer is ideal for boosting production of bio-energy specific crops," said Burnham.

VitAG has formed strategic partnerships with leading consulting, engineering and fertilizer equipment companies for the planning, engineering and construction of the VitAG facilities, and for the design and fabrication of the process equipment, respectively; and with Ferrate Treatment Technologies, LLC, manufacturer of a unique biosolids deodorizer.

About Denham Capital:

Denham Capital is a leading global private equity firm, with offices in Boston, Houston, Short Hills, New Jersey and London. With approximately $4.3 billion of invested and committed capital, Denham makes direct investments in all segments of the energy and commodities value chain, including oil and gas, mining, timber, power, carbon assets and energy-related infrastructure and services. The firm invests globally, with investments currently in the US, Canada, South America, Europe, Russia/CIS, Asia and Australia, and across all parts of the capital structure and all stages of the corporate and asset lifecycle, from development projects to mature, operating businesses. Denham typically targets investments in the $50 million to $250 million range. For more information about Denham Capital, visit HYPERLINK "http://www.denhamcapital.com/" http://www.denhamcapital.com. Denham Capital does not provide investment advisory services to the public.

Contacts:

VitAG Corporation, Jeffrey C. Burnham, PhD, (803) 652-0990, jburnham@vitagcorp.com

Denham Capital Management, Gina Sorice, CJP Communications, (212) 279-3115 ext 243, gsorice@cjpcom.com


'/>"/>
SOURCE Denham Capital; VitAG Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Bionovo to Present at BMO Capital Markets 2008 Focus on Healthcare Conference
2. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
3. Sangamo BioSciences to Present at the BMO Capital Markets Focus on Healthcare Conference
4. VNUS Medical Technologies to Present at BMO Capital Markets 2008 Focus on Healthcare Conference
5. 2008 Kansas Day of Innovation Featuring the Fifth Annual Great Plains Capital Conference Scheduled for September
6. Arbel Medical has Completed a $4.5 million Round of Capital Raising led by Giza Venture Capital Fund
7. Insmed Retains RBC Capital Markets as Strategic Financial Advisor
8. Commercial Launch of Lexiscan(TM) (Regadenoson) Injection Triggers $10 Million Milestone Payment from TPG-Axon Capital to CV Therapeutics
9. WorldHeart Enters into a Recapitalization Agreement and Receives Bridge Financing
10. Immtech Pharmaceuticals and Beijing Capital Medical University Announce Joint Venture to Provide Contract Research Services in China
11. Deloitte Agrees to Acquire Recombinant Capital, A Leading Life Sciences Subscription Database and Advisory Services Firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... San Francisco, CA (PRWEB) , ... June 23, ... ... capture (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase ... DIA Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting ...
(Date:6/23/2016)... June 23, 2016 ReportsnReports.com ... report to its pharmaceuticals section with historic and ... and much more. Complete report on ... pages, profiling 15 companies and supported with 261 ... http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The Global Cell ...
Breaking Biology Technology:
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... provide their customers enhanced security to access and ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
Breaking Biology News(10 mins):